Recently, AstraZeneca announced a $2.5 billion investment plan to establish its sixth global strategic R&D center in Beijing, while expanding biotech innovation collaborations and local manufacturing. Concurrently, as the most significant platform connecting AstraZeneca's global R&D with China's scientific and innovative capabilities, AstraZeneca China R&D Day was held for the first time in Beijing on March 28–29. The event focused on AstraZeneca's global R&D strategy in oncology, clinical research approaches, cutting-edge advancements, and future collaboration opportunities, further strengthening pharmaceutical R&D partnerships and ecosystem co-construction in China.

The two-day conference featured a keynote forum and five breakout sessions, comprehensively showcasing AstraZeneca's global oncology R&D strategy and development direction. Discussions centered on hot topics, including high-incidence cancers in China, radiopharmaceuticals, cell therapy, data science, and artificial intelligence. The conference facilitated in-depth exchanges and collaboration opportunities on expanding foundational innovation in oncology research, enhancing drug development, translational medicine, and innovative technology partnerships. Nearly 80 leading Chinese experts, scholars, representatives from biotech companies, and AstraZeneca executives gathered for comprehensive discussions and knowledge sharing. The event delivered rich, practical content and compelling insights, attracting over 600 on-site attendees and over 20,000 online viewers.

As a member of the AstraZeneca ecosystem, bioGenous has consistently focused on the research, development, and application of organoid technology, dedicated to providing more precise and effective model support for cancer research. The invitation to participate in AstraZeneca China's R&D Day event “Dedicated to Conquering Cancer” not only reflects bioGenous’ leading position in organoid technology but also highlights the significance of China's local innovation capabilities in global pharmaceutical R&D. Moving forward, leveraging the AstraZeneca ecosystem, bioGenous will fully utilize its technological strengths to contribute significantly to the innovation and advancement of cancer diagnosis and treatment. This commitment aims to propel progress in China's pharmaceutical R&D and bring greater hope and well-being to patients worldwide